

# EMA contribution to a One Health approach addressing antimicrobial resistance


The veterinary perspective





#### Content

- 1. AMR in the European context
- 2. Sales data
- 3. Better regulation
- 4. Upcoming new actions for veterinary medicines Regulation (EU) 2019/6
- 5. International collaboration





## AMR in the European context – a One Health Approach

#### EU One Health Action Plan against AMR -

https://ec.europa.eu/health/antimicrobial-resistance/eu-action-on-antimicrobial-resistance en

EU Guidelines on prudent use of antimicrobials in human health <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52017XC0701(01)">https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:52017XC0701(01)</a>

EMA: - human and veterinary medicines authorisation

- surveillance of veterinary antimicrobial consumption (ESVAC)
- better regulation of human & veterinary medicines


ECDC: - EARS-Net - EU antimicrobial resistance surveillance (human),

- ESAC-Net EU surveillance of a consumption (human)
- FWD-Net EU Food- & Waterborne Diseases & Zoonoses net

EFSA: - resistance monitoring in zoonotic bacteria (veterinary)

- Scientific Network for Zoonosis Monitoring Data

EMA-ECDC-EFSA together: JIACRA reports (joint inter-agency antimicrobial consumption and resistance analysis)



# European Surveillance of Veterinary Antimicrobial Consumption (ESVAC)

- Launched in 09/2009 by the EMA as a project mandated by the EC with 9 countries
- 2020: 10<sup>th</sup> report, 31 countries (EU 27 plus CH, IS, NO, UK)
- Between 2011 and 2018, sales have reduced by:
  - ↓ 34% for **overall** sales;
  - ↓ 24% for third and fourth generation cephalosporins;
  - ↓ 70% for **polymyxins**;
  - ↓ 4% for fluoroquinolones;
  - ↓ 74% for other **quinolones**.
- Mixed picture across the EU, even increase over time in a few countries

Spatial distribution of overall sales of all antimicrobials for foodproducing animals, in mg/PCU, for 31 countries, for 2018





## 3. Better regulation of veterinary medicines

The Committee's for Veterinary Medicinal Products CVMP strategy on antimicrobials (2021-2025 in development)

#### CVMP guidelines on

- <u>Efficacy of antimicrobial VMPs</u>
- AMR public health risk assessment
- SPC of antimicrobial VMPs


#### Additional resources:

- EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA)
- Updated <u>AMEG categorisation of</u> antibiotics
- CVMP Reflection paper on authorisation of Alternatives to Antibiotics
- AMEG advice on <u>preliminary risk profiling</u> for new veterinary antimicrobials



## 4. Regulation (EU) 2019/6 on veterinary medicinal products


Replaces Directive 2001/82/EC within the overall aim of achieving 'Better Regulation' in the EU



# 4. Regulation (EU) 2019/6 on VMPs




### **Timeline**



# 4. Regulation (EU) 2019/6 on VMPs



We must increase awareness of the social and economic relevance of the activities related to veterinary medicines – most of what we do has an effect on people.



## Food security

Healthy livestock for food production industry

## Food safety

Safety of food derived from animals through evaluation of MRLs & setting of withdrawal periods for veterinary medicines to be used in foodproducing animals

#### Prudent use

Foster prudent use of antibiotics in animals

#### Antibiotics

Safeguarding antibiotics that continue to work for humans

#### Healthy pets

Healthy pet animals have a positive effect on human health

### Environment

Protecting the environment from harmful substances in veterinary medicines

# Animal welfare

Animal welfare in clinical studies (through 3Rs policies and veterinary medicines)

# 4. Regulation (EU) 2019/6 on VMPs



## Specific actions for AMR

- <u>ldı.</u>
- Extended collection of antimicrobial sales data

- 0
- Collection of data on use of antimicrobials in animals (stepwise approach)
- X X X
- List of antimicrobials reserved for human use based on specific criteria (under development)
- Restriction of legally allowed use outside the terms of the marketing authorisation for certain antimicrobials



#### 5. International collaboration



# Any questions?

#### Further information

ivo.claassen@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands Telephone +31 (0)88 781 6000Send us a question Go to <a href="https://www.ema.europa.eu/contact">www.ema.europa.eu/contact</a>

